Bioenvision (BIVN) Reports a Q4 Loss
More News related to BIVN
- Wachovia Starts Bioenvision (BIVN) at Market Perform
- Bioenvision (BIVN) Reports a Q4 Loss
- Bioenvision's (BIVN) Former General Counsel Files Action in NY Supreme Court Against the Company
- Genzyme (GENZ) Announces Completion of Tender Offer for Bioenvision
- Rodman & Renshaw Downgardes Bioenvision (BIVN) to Market Perform
More News related to Earnings
- Green Mountain (GMCR) Will Likely Win Diedrich Coffee (DDRX) Bidding War - Analyst
- SkyPeople (SPU) Acquires Yingkou Trusty Fruits in $3.3M Transaction
- GE (GE) Said to Restart NBC Universal Acquisition Talks -WSJ
- Diedrich Coffee (DDRX) Comments on Green Mountain Coffee Roasters' (GMCR) Revised Offer
- Peet's (PEET) Issues Statement Following News Diedrich (DDRX) Says Green Mountain (GMCR) Revised Offer is 'Superior'
Bioenvision, Inc. (Nasdaq: BIVN) reports a Q4 loss of $0.17 vs. consensus for $0.15 loss. Revenues were $6.75 million vs. $5.67 million consensus.
(The 2007 fourth quarter net loss included a one-time non-cash impairment loss equal to the carrying value of Suvus® as an intangible asset of approximately $3,311,000)
Related Categories
EarningsStocks Mentioned
-0.03Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
